No Established Correlation Between Atrial Septal Aneurysm and Hypertrophic Cardiomyopathy
An atrial septal (fossa ovalis) aneurysm has no established correlation with hypertrophic cardiomyopathy (HCM). These are distinct cardiac entities that occur independently, and the available evidence does not support a pathophysiologic or epidemiologic link between them.
Evidence Analysis
Atrial Septal Aneurysm: A Common Incidental Finding
Atrial septal aneurysm (ASA) is a relatively common structural variant found in the general population:
- Prevalence in normal hearts: ASA occurs in approximately 1.9-2.5% of the general population, most commonly associated with patent foramen ovale (PFO) 1, 2, 1
- Primary associations: ASA is predominantly linked to cryptogenic stroke risk through paradoxical embolism, particularly when coexisting with PFO 1
- Clinical significance: The main concern with ASA relates to thromboembolic risk and arrhythmias, not cardiomyopathy 3
HCM: A Distinct Genetic Cardiomyopathy
HCM is a genetic sarcomeric disease with its own characteristic structural abnormalities:
- Typical structural features: HCM is characterized by left ventricular hypertrophy, diastolic dysfunction, mitral regurgitation, and left ventricular outflow tract obstruction 4, 5
- Associated aneurysms: When aneurysms occur in HCM, they are apical or basal left ventricular aneurysms, not atrial septal aneurysms 6, 7
- Distinct pathophysiology: HCM-related aneurysms result from myocardial ischemia, fibrosis, and abnormal wall stress—mechanisms unrelated to atrial septal morphology 4, 6
Isolated Case Reports Do Not Establish Correlation
The evidence base includes only isolated case reports of concurrent findings:
- One case report describes an ASD (not ASA) in a patient with apical HCM and coronary spasm 8
- Another describes a membranous ventricular septal aneurysm (not atrial) in a child with Noonan syndrome and HCM 9
- These represent coincidental findings rather than pathophysiologic associations
Recent Research on ASA Does Not Mention HCM
Contemporary research on ASA focuses entirely on:
- Atrial cardiomyopathy and atrial fibrillation risk 10
- Thromboembolic complications 3
- Association with PFO and stroke 11, 12
Notably absent: Any mention of HCM as a related condition in comprehensive ASA reviews 3
Clinical Implications
When Both Are Present
If you encounter a patient with both ASA and HCM:
- Treat as independent conditions: Manage each according to its own evidence-based guidelines
- HCM management priorities 4, 5:
- Risk stratify for sudden cardiac death
- Assess for left ventricular outflow tract obstruction
- Monitor for atrial fibrillation (common in HCM at 20-25% prevalence) 13
- Evaluate for apical/basal LV aneurysms (not ASA)
- ASA management priorities 1, 3:
- Evaluate for associated PFO
- Assess thromboembolic risk if cryptogenic stroke has occurred
- Consider anticoagulation if atrial fibrillation develops
Important Distinction: Atrial Fibrillation
Both conditions can independently lead to atrial fibrillation:
- HCM: 20-25% develop AF due to left atrial enlargement and diastolic dysfunction 13
- ASA: May contribute to atrial arrhythmias through atrial cardiomyopathy mechanisms 10
This shared complication does not imply the structural abnormalities are related.
Common Pitfall to Avoid
Do not confuse atrial septal aneurysm with left ventricular apical aneurysm—these are completely different structures with different clinical significance. LV apical aneurysms in HCM carry high sudden death risk (2-8% per year depending on size) and require aggressive management 6. ASA does not carry this risk and is not part of the HCM phenotype.